Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Immune Monitoring and Calcineurin Inhibitor (CNI) Withdrawal in Low Risk Recipients of Kidney Transplantation

The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.

Study Overview

• Status: Terminated
• Conditions: Kidney Transplant Recipients
• Intervention / Treatment: Drug: Tacrolimus (CNI) Withdrawal; Drug: Standard Immunosuppressive Therapy

Detailed Description

Kidney transplantation is a treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients take immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. All anti-rejection medications have unwanted side effects. The purpose of this study is to evaluate the safety of slowly removing tacrolimus, a CNI.

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3A IR9
      • Health Sciences Centre
  • Ontario
    • Toronto, Ontario, Canada, M5G 2M1
      • Toronto General Hospital
• United States
  • California
    • Los Angeles, California, United States, 90055
      • University of California Los Angeles
  • Connecticut
    • New Haven, Connecticut, United States, 06520-8029
      • Yale University School of Medicine
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Brigham & Women's Hospital
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan Hospital
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University
  • New York
    • New York, New York, United States, 10029
      • Mount Sinai School of Medicine
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic Foundation
    • Cleveland, Ohio, United States, 44106-5048
      • University Hospitals of Cleveland
  • Texas
    • Houston, Texas, United States, 77030
      • The Methodist Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

INCLUSION CRITERIA -

Initial Enrollment/Screening: Patients who meet all of the following criteria are eligible for enrollment as study subjects:

• Subject must be able to understand and provide written informed consent;
• Primary living-donor (related or unrelated) kidney transplant recipients;
• Peak flow-based PRAs for class I and class II <30%(performed by local center);
• Current (within 8 weeks prior to transplantation) flow-based PRAs for class I and class II <30% (performed by local center);
• No donor specific antibody by flow solid phase method on the peak PRA serum (if serum available), or on the current PRA serum (within 8 weeks prior to transplantation) performed by central core laboratory. If the sera for the peak PRA is not available, then only the current PRA serum will be tested;
• Negative T-cell and B-cell crossmatch by flow cytometry (performed by local center);
• Female subjects of childbearing potential must have a negative pregnancy test (urine or serum) upon study entry;
• Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control while participating in the study.

Inclusion Criteria for Randomization:

Participants who meet all of the following criteria are eligible for randomization:

• No history of acute rejection episodes;
• The pre-randomization protocol biopsy should confirm no rejection, including borderline rejection (based on the central pathology read);
• No donor specific antibody as detected by flow solid phase method (performed by the central core laboratory).

EXCLUSION CRITERIA -

Initial Enrollment/Screening:

Participants who meet any of these criteria are not eligible for enrollment as study subjects:

• Recipient of multiple organ transplants;
• Prior history of organ transplantation;
• Deceased-donor source;
• Any condition that would preclude protocol biopsies;
• HLA identical recipients;
• Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
• Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
• Inability or unwillingness to comply with study protocol;
• Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
• Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of prior to study entry.

Exclusion Criteria for Randomization:

Participants who meet any of these criteria are not eligible for randomization:

• Subjects who receive less than 4.5mg/kg of Rabbit ATG (Thymoglobulin®) induction therapy;
• Subjects who test positive for BKV by PCR in the blood at 6 months post-transplant;
• Any condition that would preclude protocol biopsies;
• Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
• Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
• Inability or unwillingness of a subject to give written informed consent or comply with study protocol;
• Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
• Subjects who receive less than 1500 mg daily of Mycophenolate Mofetil (CellCept®) or equivalent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Tacrolimus (CNI) Withdrawal; Subjects randomized (2:1) to tacrolimus (CNI) withdrawal. Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal.	Drug: Tacrolimus (CNI) Withdrawal; Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.; Other Names: Thymoglobulin®; mycophenolate mofetil; CellCept®; ATG Induction,Tacrolimus (CNI), MMF and Prednisone, Followed by CNI Withdrawal; rabbit antithymocyte globulin (RATG); calcineurin inhibitor (CNI); Drug: Standard Immunosuppressive Therapy; Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.; Other Names: Thymoglobulin®; mycophenolate mofetil; CellCept®; rabbit antithymocyte globulin (RATG); calcineurin inhibitor (CNI); ATG induction,Tacrolimus (CNI), MMF and Prednisone
ACTIVE_COMPARATOR: Standard Immunosuppressive Therapy; Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal. Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur.	Drug: Standard Immunosuppressive Therapy; Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.; Other Names: Thymoglobulin®; mycophenolate mofetil; CellCept®; rabbit antithymocyte globulin (RATG); calcineurin inhibitor (CNI); ATG induction,Tacrolimus (CNI), MMF and Prednisone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Incremental IF/A Scores >2 at 24 Months Post-Randomization	The investigators were not able to assess this outcome, the effect of the intervention on interstitial fibrosis/tubular atrophy (IF/TA; on a 2-year graft biopsy) due to the study's premature termination by the Data Safety Monitoring Board (DSMB) because of absence of equipoise on the basis of predetermined stopping rules.	IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Estimated GFR Using the Chronic Kidney Disease Epidemiology (CKD-EPI) Equation	Estimated glomerular filtration rate (eGFR) is a test to measure the level of kidney function. In this measure, the effects of tacrolimus withdrawal on long-term kidney function was assessed by comparing absolute 24 month eGFR (18 months post-randomization) and change in eGFR from 6 to 24 months (randomization to 18 months randomization). Lower numbers indicate poorer kidney function	6 months post-transplantation, 24 months post-transplantation
Incidence of Acute Rejection	Acute renal allograft rejection is defined as histological reading of borderline or greater determined by the local pathology laboratory. Participants suspected of having a rejection episode on the basis of clinical signs, symptoms, or on the basis of laboratory tests, had a renal ultrasound and underwent a renal transplant biopsy. Any detection of acute cellular rejection or acute humoral rejection resulted in participants in the 'Randomized to Tacrolimus Withdrawal' group to be restarted on tacrolimus and followed per the reduced follow-up schedule of events.	6 to 18 months post-randomization
Allograft Survival Rate	Allograft survival is defined as participants who did not need to be re-transplanted or placed on dialysis due to the failure of their allograft transplantation during the course of this study.	6 to 18 months post-randomization
Participant Survival Rate	Number of participants who did not die within the course of this study.	6 to 18 months post-transplantation
Percentage of Participants With New Donor Specific Antibodies (DSAs)	Donor specific antibodies are antibodies that are directed against antigens expressed on donor organs. These antibodies can result in an immune attack on the transplanted organ, increasing risk of graft loss and/or rejection.	6 to 18 months post-randomization
Percentage of Participants With Donor-Specific Memory Using Elispot	This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.	6 to 18 months post-randomization
Percentage of Participants in the Experimental Arm Off Tacrolimus	Participants in the 'Randomized to Tacrolimus Withdrawal' group were considered fully withdrawn once they no longer received any doses of tacrolimus. Participants met this endpoint if they did not resume taking tacrolimus as of 18 months post randomization with stable allograft function and without rejection of donor-specific antibodies.	18 months post-randomization
Incremental Change in IF/TA Scores	This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.	6 to 18 months post-transplant
Measurement of Urinary Parameters Before and After Randomization	This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.	6 months post-transplantation to 18 months post-randomization

Collaborators and Investigators

• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Collaborators: Clinical Trials in Organ Transplantation
• Investigators: Study Chair: Donald Hricik, MD, University Hospitals Cleveland Medical Center

Publications and helpful links

General Publications

• Hricik DE, Formica RN, Nickerson P, Rush D, Fairchild RL, Poggio ED, Gibson IW, Wiebe C, Tinckam K, Bunnapradist S, Samaniego-Picota M, Brennan DC, Schroppel B, Gaber O, Armstrong B, Ikle D, Diop H, Bridges ND, Heeger PS; Clinical Trials in Organ Transplantation-09 Consortium. Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. J Am Soc Nephrol. 2015 Dec;26(12):3114-22. doi: 10.1681/ASN.2014121234. Epub 2015 Apr 29.

Helpful Links

• National Institute of Allergy and Infectious Diseases (NIAID)
• Clinical Trials in Organ Transplantation (CTOT)

Study record dates

Study Major Dates

• Study Start: November 1, 2010
• Primary Completion (ACTUAL): May 1, 2015
• Study Completion (ACTUAL): May 1, 2015

Study Registration Dates

• First Submitted: January 20, 2012
• First Submitted That Met QC Criteria: January 20, 2012
• First Posted (ESTIMATE): January 25, 2012

Study Record Updates

• Last Update Posted (ACTUAL): September 11, 2017
• Last Update Submitted That Met QC Criteria: August 10, 2017
• Last Verified: August 1, 2017

More Information

Terms related to this study

• Keywords: calcineurin inhibitors (CNIs); recipients of living-donor kidney allografts; antithymocyte globulin (ATG) induction; CNI withdrawal
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Immunologic Factors; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antitubercular Agents; Antibiotics, Antitubercular; Prednisone; Tacrolimus; Mycophenolic Acid; Thymoglobulin; Antilymphocyte Serum; Immunosuppressive Agents; Calcineurin Inhibitors
• Other Study ID Numbers: DAIT CTOT-09